B+
Bull case
25%
Probability
Target price
$94.00
Analysis reference price unavailable
Analysis 2026-10-29 · RankAlpha Sentiment Codex
WGS
GeneDxFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$70.00
Analysis reference price unavailable
Analysis 2026-10-29 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$43.00
Analysis reference price unavailable
Analysis 2026-10-29 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-29
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+61.0
Score
AI commentary
Recent company announcements support a modestly constructive product narrative, but the supposed T+3 earnings follow-up is premature: GeneDx scheduled Q3 results for November 9. A Q3 price reaction, earnings surprise, transcript, and post-print analyst revisions are therefore unavailable. Zero-valued sentiment fields denote unavailable measurements, not neutral readings. The $64.69 price anchor is dated October 28.
RankAlpha Sentiment Codex - 2026-10-29
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-09eventNovember 9 third-quarter resultsHigh impact
GeneDx says it will report Q3 results after the close on November 9, not October 26 as the automated follow-up trigger assumed. The test is delivery against its prior Q3 guidance of $122 million–$124 million revenue, 33,200 exome/genome tests, approximately 70% adjusted gross margin, and approximately $2 million adjusted net income. No Q3 result or surprise is available yet. [#IR-2026-10-23] [#SEC-8K-2026-08-03] [#8-K-2026-08-03] Sources: https://ir.genedx.com/news-releases/news-release-details/genedx-report-third-quarter-2026-financial-results-monday ; https://www.sec.gov/Archives/edgar/data/1818331/000162828026051852/exhibit991-q22026pressrele.htm
2027-10-29catalystEasy Order utilizationHigh impact
GeneDx introduced Easy Order to simplify ExomeDx and chromosomal microarray ordering by general pediatricians. Subsequent test-volume and exome/genome revenue trends—not the product announcement alone—must establish commercial impact. The date is an assessment horizon, not a company-promised milestone. [#IR-2026-10-02] Source: https://ir.genedx.com/news-releases/news-release-details/genedx-introduces-easy-order-aap-2026-simplify-genomic-testing
2027-10-29catalystLong-read sequencing developmentMedium impact
GeneDx announced plans to enhance its genome-testing portfolio with long-read sequencing. A launch date, reimbursement economics, and revenue contribution were not established in the checked source; this remains a development watch item. The date is an assessment horizon. [#IR-2026-10-20] Source: https://ir.genedx.com/news-releases/news-release-details/genedx-expands-diagnostic-leadership-long-read-genome-sequencing
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-29 • Updated nightlySource: Internal modelMethodology